Lumosa Therapeutics
Lumosa Therapeutics is a clinical-stage pharmaceutical company dedicated to creating solutions for neurological and oncological diseases with urgent unmet medical needs. They focus on innovative therapies, building pipelines through licensing and collaboration, and aim to be a global leader in neuroscience, especially in stroke treatment.
Industries
Nr. of Employees
medium (51-250)
Lumosa Therapeutics
115 Taipei City Nangang District, Yuanqu Street 3-2, 4th Floor, South Port Software Park Phase II, H Building
Patents
Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-12059448-B2
View DetailsPharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-11707501-B2
View DetailsPharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-11338008-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-11241424-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-11234974-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-10183018-B2
View Details
Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-12059448-B2
View DetailsPharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-11707501-B2
View DetailsPharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-11338008-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-11241424-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-11234974-B2
View DetailsPharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US-10183018-B2
View DetailsProducts
Stroke therapy candidate (recanalization agent for acute ischemic stroke)
Clinical‑stage therapeutic candidate designed to restore occluded cerebral blood flow while aiming to reduce hemorrhagic risk; advanced through IND and Phase 2 clinical studies in multiple regions.
Extended‑release injectable analgesic for postoperative pain
An extended‑release injectable analgesic product developed for postoperative pain control with reported regulatory approvals and distribution agreements in multiple countries.
Therapeutic candidate for uremic pruritus
Development‑stage candidate targeting uremic pruritus listed in the neuroscience pipeline.
Oncology solid tumor candidate
Development‑stage candidate for solid tumor indications listed in the oncology pipeline.
Fusion protein therapeutic candidate for pancreatic cancer (orphan‑designated)
Biologic fusion‑protein therapeutic developed for pancreatic cancer that has received orphan drug designation from a regulatory authority.
Stroke therapy candidate (recanalization agent for acute ischemic stroke)
Clinical‑stage therapeutic candidate designed to restore occluded cerebral blood flow while aiming to reduce hemorrhagic risk; advanced through IND and Phase 2 clinical studies in multiple regions.
Extended‑release injectable analgesic for postoperative pain
An extended‑release injectable analgesic product developed for postoperative pain control with reported regulatory approvals and distribution agreements in multiple countries.
Therapeutic candidate for uremic pruritus
Development‑stage candidate targeting uremic pruritus listed in the neuroscience pipeline.
Oncology solid tumor candidate
Development‑stage candidate for solid tumor indications listed in the oncology pipeline.
Fusion protein therapeutic candidate for pancreatic cancer (orphan‑designated)
Biologic fusion‑protein therapeutic developed for pancreatic cancer that has received orphan drug designation from a regulatory authority.
Services
Identification, negotiation and execution of licensing and co‑development agreements to advance drug candidates across territories and development stages.
End‑to‑end clinical program support including trial design and conduct, preparation of IND/NDA documents, and pharmacovigilance setup.
Support for coordination with international distributors and regional partners to enable product availability and territory-specific commercialization.
Identification, negotiation and execution of licensing and co‑development agreements to advance drug candidates across territories and development stages.
End‑to‑end clinical program support including trial design and conduct, preparation of IND/NDA documents, and pharmacovigilance setup.
Support for coordination with international distributors and regional partners to enable product availability and territory-specific commercialization.
Expertise Areas
- Clinical trial management
- Neuroscience drug development (stroke therapeutics)
- Oncology biologic development
- Formulation development for injectable drugs
Key Technologies
- Antibody and protein engineering
- Fusion protein therapeutics
- Extended‑release injectable formulations
- Preclinical translational models